Anti-Angiogenic Effects of Diltiazem, Imatinib, and Bevacizumab in the CAM Assay

Yıldız Ç., Demirci F., Akın Polat Z., Göze İ. A.

International Journal of Scientific and Research Publications, cilt.3, sa.8, ss.1-8, 2013 (Hakemli Dergi)

Özet

angiogenesis that plays important roles in a variety of physiological processes is strictly delimited and finely tuned by a balance of pro-angiogenic and anti-angiogenic factors. Angiogenesis is essential for viability, growth, invasion and metastasis of tumors. The chorioallantoic membrane model is considered to be a valuable method for investigation of antiangiogenic effects of drugs and other substances. The aim of the present study is to investigate the anti-angiogenic effects of a calcium channel blocker (diltiazem), a tyrosine kinase inhibitor (imatinib), and a vascular endothelial growth factor inhibitor (bevacizumab) with the means of the chicken chorioallantoic membrane (CAM) model. Each drug was administered onto the chorioallantoic membrane at the concentrations of 10-4M, 10-5M, and 10-6M on 8th day of incubation. After 24 h, development of the blood vessels under a stereo-microscope was investigated. The evaluations were performed using a scoring system. We evaluated anti-angiogenic effects of the drugs in two ways according to their average anti-angiogenic effect and comparison of median anti-angiogenic score. These two angiogenesis evaluation techniques provided similar results to measure antiangiogenic effects of the study drugs. Bevacizumab has the strongest anti-angiogenic effect compared to the diltiazem and imatinib, and althought not reaching statistical significance imatinib has a strong anti-angiogenic effect than that of the diltiazem.